RT Journal Article
SR Electronic
T1 Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.21.20199109
DO 10.1101/2020.09.21.20199109
A1 Purbita Bandopadhyay
A1 Ranit D’Rozario
A1 Abhishake Lahiri
A1 Jafar Sarif
A1 Yogiraj Ray
A1 Shekhar Ranjan Paul
A1 Rammohan Roy
A1 Rajshekhar Maiti
A1 Kausik Chaudhuri
A1 Saugata Bagchi
A1 Ayan Maiti
A1 Md. Masoom Perwez
A1 Biswanath Sharma Sarkar
A1 Devlina Roy
A1 Rahul Chakraborty
A1 Janani Srinivasa Vasudevan
A1 Sachin Sharma
A1 Durba Biswas
A1 Chikam Maiti
A1 Bibhuti Saha
A1 Prasun Bhattacharya
A1 Rajesh Pandey
A1 Shilpak Chatterjee
A1 Sandip Paul
A1 Dipyaman Ganguly
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.21.20199109.abstract
AB In a randomized control trial on convalescent plasma therapy (CPT) in severe COVID-19, we characterized the nature, in terms of abundance of forty eight cytokines, and dimensions, in terms of their interrelationships, of the hyper-immune activation-associated ‘cytokine storm’ in patients suffering from acute respiratory distress syndrome. We found reduced plasma level of the chemokine MCP3 to be a key correlate for clinical improvement, irrespective of therapeutic regimen. We also identified an anti-inflammatory role of CPT independent of its neutralizing antibody content, and a linear regression analysis revealed that neutralizing antibodies as well as the anti-inflammatory effect of CPT both contribute to marked immediate reductions in hypoxia, as compared to patients on standard therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinical Trial Registry of India No. CTRI/2020/05/025209Funding StatementFunding for this study was from Council of Scientitific Industrial Research (CSIR), Govt. of India (MLP-129)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study had ethical approval from the Institutional Review Boards of CSIR-Indian Institute of Chemical Biology, Kolkata, India (IICB/IRB/2020/3P), Institutional Review Boards of Medical College Hospital, Kolkata (MC/KOL/IEC/NON-SPON/710/04/2020), India and Infectious Disease & Beleghata General Hospital (ID & BG Hospital), Kolkata, India (IDBGH/Ethics/2429). The RCT was approved by Central Drugs Standard Control Organisation (CDSCO) under Directorate General of Health Services, Ministry of Health & Family Welfare, Govt. of India (approval no. CT/BP/09/2020) and registered with Clinical Trial Registry of India (CTRI), under Indian Council of Medical Research, India.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available with the corresponding author and will be shared on request.